Mikael Bronnegard, CEO of NeuroVive Pharmaceutical said: " I am delighted to have appointed Jan Nilsson to the position of Chief Operating Officer, significantly strengthening our senior management team during what is a very exciting period in NeuroVive ' s development. With CicloMulsion® currently in Phase III clinical trial, NeuroSTAT® now entering a Phase IIa clinical study and the recent collaboration agreement with Sihuan Pharmaceutical for the commercialization of these products in China, NeuroVive is making significant strides forward in the execution of our product development and commercial strategies. Jan is an excellent addition to NeuroVive ' s management team and one that will help to drive the Company towards the further realization of its corporate goals and to maximize shareholder value by delivering our novel medicines to market. "About NeuroVive Pharmaceutical AB NeuroVive Pharmaceutical AB ( http://www.neurovive.com) a leading mitochondrial medicine company is developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection. NeuroVive's leading products are special formations of the cyclophilin inhibitor cyclosporine, which act to limit secondary tissue damage caused by myocardial infarction and traumatic brain injuries by preventing the destruction of mitochondria in distressed cells and the cascade of intracellular biochemical events that lead to cell death. NeuroVive's lead product is CicloMulsion®, the first cyclophilin inhibitor for the treatment of reperfusion injuries. CicloMulsion® is currently in a 1000 patient Phase III clinical trial evaluating its ability to reduce reperfusion injuries in patients with myocardial infarction. NeuroVive is also developing NeuroSTAT®, which is entering a Phase IIa clinical trial in patients with severe traumatic brain injury. Both indications have huge medical need and for which there are currently no approved pharmaceutical treatment options.